Cancer gene and immunotherapy: recent developments (Q33717186)

28 July 2017

1 reference

title

Cancer gene and immunotherapy: recent developments (English)

1 reference

28 July 2017

1 reference

Jantscheff P

1 reference

28 July 2017

Herrmann R

series ordinal

1 reference

28 July 2017

Rochlitz C

series ordinal

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

78-85

1 reference

Tumor immunotherapy by vaccination with cytokine gene transfected cells.

28 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02785840

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02785840

TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective

21 January 2018

1 reference

12 December 2020

Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes

1 reference

12 December 2020

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides

1 reference

12 December 2020

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

1 reference

12 December 2020

Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.

1 reference

12 December 2020

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

1 reference

12 December 2020

Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

1 reference

12 December 2020

Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

1 reference

12 December 2020

MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.

1 reference

12 December 2020

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

12 December 2020

An eosinophil-dependent mechanism for the antitumor effect of interleukin-4

1 reference

12 December 2020

Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells

1 reference

12 December 2020

Perspectives on the role of MHC antigens in normal and malignant cell development

1 reference

12 December 2020

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

1 reference

12 December 2020

Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies

1 reference

12 December 2020

Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts

1 reference

12 December 2020

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

1 reference

12 December 2020

1 reference

12 December 2020

T cell defined tumor antigens

1 reference

12 December 2020

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1 reference

12 December 2020

Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine.

1 reference

12 December 2020

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

12 December 2020

Identification of human cancers deficient in antigen processing

1 reference

12 December 2020

Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.

1 reference

12 December 2020

Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.

1 reference

12 December 2020

The c-myb proto-oncogene: a novel target for human gene therapy

1 reference

12 December 2020

Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes

1 reference

12 December 2020

Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression

1 reference

12 December 2020

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.

1 reference

12 December 2020

Immune response against tumors.

1 reference

12 December 2020

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

1 reference

12 December 2020

In vitro and in vivo antitumor effects of retrovirus-mediated herpes simplex thymidine kinase gene-transfer in human medulloblastoma

1 reference

12 December 2020

Transfection of major histocompatibility complex class I and class II genes causes tumour rejection

1 reference

12 December 2020

Nomenclature for factors of the HLA System, 1996.

1 reference

12 December 2020

Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein

1 reference

12 December 2020

MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes

1 reference

12 December 2020

Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay

1 reference

12 December 2020

Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

1 reference

12 December 2020

Inhibition of tumor growth by histoincompatible cells expressing interleukin-2

1 reference

12 December 2020

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

1 reference

12 December 2020

Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes

1 reference

12 December 2020

A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

1 reference

12 December 2020

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

12 December 2020

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine

1 reference

12 December 2020

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

12 December 2020

Stromal cells maintain the radioprotective capacity of CFU-S during retroviral infection.

1 reference

12 December 2020

The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens

1 reference

12 December 2020

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

1 reference

12 December 2020

Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals

1 reference

12 December 2020

Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells

1 reference

12 December 2020

Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study

1 reference

12 December 2020

Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency

1 reference

12 December 2020

Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity

1 reference

12 December 2020

Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells

1 reference

12 December 2020

Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis

1 reference

12 December 2020

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

12 December 2020

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

1 reference

12 December 2020

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

12 December 2020

Origin, maturation and antigen presenting function of dendritic cells.

1 reference

12 December 2020

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients

1 reference

12 December 2020

Serological identification of human tumor antigens

1 reference

12 December 2020

Lymphocyte-Melanoma Interaction: Role of Surface Molecules

1 reference

12 December 2020

Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumors

1 reference

12 December 2020

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

1 reference

12 December 2020

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

1 reference

12 December 2020

Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways

1 reference

12 December 2020

IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells

1 reference

12 December 2020

Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines

1 reference

12 December 2020

Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity

1 reference

12 December 2020

Cancer vaccines: the interleukin 2 dosage effect

1 reference

12 December 2020

Cancer vaccines based on the identification of genes encoding cancer regression antigens

1 reference

12 December 2020

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

12 December 2020

Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.

1 reference

12 December 2020

Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones

1 reference

12 December 2020

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

1 reference

12 December 2020

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

1 reference

12 December 2020

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation

1 reference

12 December 2020

P53 tumor suppressor gene therapy for cancer

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.

1 reference

12 December 2020

Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma

1 reference

12 December 2020

A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model

1 reference

12 December 2020

Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2.

1 reference

12 December 2020

Stabilization of beta-catenin by genetic defects in melanoma cell lines

1 reference

12 December 2020

Tumor antigens recognized by T cells

1 reference

12 December 2020

Loss of HLA haplotype and B locus down-regulation in melanoma cell lines

1 reference

12 December 2020

Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and g

1 reference

12 December 2020

Multiple tumour-specific antigens expressed on a single tumour cell

1 reference

12 December 2020

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

12 December 2020

Structure, chromosomal localization, and expression of 12 genes of the MAGE family

1 reference

12 December 2020

Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice

1 reference

12 December 2020

Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells

1 reference

12 December 2020

Murine interleukin-4 displays potent anti-tumor activity in vivo

1 reference

12 December 2020

Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance.

1 reference

12 December 2020

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

12 December 2020

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

12 December 2020

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1 reference

12 December 2020

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

1 reference

12 December 2020

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

1 reference

12 December 2020

Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.

1 reference

12 December 2020

Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.

1 reference

12 December 2020

Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.

1 reference

12 December 2020

HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance

1 reference

12 December 2020

The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02785840

1 reference

Dimensions Publication ID

28 July 2017

1026283352

0 references

1 reference